Yongshun Chen
Overview
Explore the profile of Yongshun Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
66
Citations
3461
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tian Y, Shi W, Wang J, Zhang W, Xia L, Gao L, et al.
Exp Hematol Oncol
. 2025 Mar;
14(1):34.
PMID: 40075410
In this investigator-initiated, prospective, exploratory study, biomarkers predictive of clinical outcomes of first-line immune checkpoint inhibitor (ICI, nivolumab or pembrolizumab) plus XELOX(oxaliplatin and capecitabine) were identified in human epidermal growth...
2.
Zhang W, Wang J, Shi W, Qiu H, Ke S, Tian Y, et al.
Mol Cancer Ther
. 2025 Feb;
PMID: 39895587
In this prospective, open-label, exploratory study (RENMIN-213), patients with previously untreated, HER2-negative, advanced G/GEJ adenocarcinoma patients with signet ring cell carcinoma or peritoneal metastasis, were enrolled to receive 8 cycles...
3.
Qiu H, Gao L, Shi W, Wang J, Li B, Ke S, et al.
Cancer Lett
. 2024 Dec;
611:217401.
PMID: 39694222
Elaiophylin is known to exert antitumor effects through certain signaling pathways; however, no reports regarding its effects on esophageal cancer are available. This study explored the effects of elaiophylin in...
4.
Yan H, Zhu H, Cai Y, Xin D, Cai G, Zou B, et al.
J Thorac Dis
. 2024 Dec;
16(11):7787-7796.
PMID: 39678850
Background: The rare incidence of small cell carcinoma of the esophagus (SCCE) makes prospective studies difficult to conduct, the efficacy of existing standard treatment regimens for SCCE is therefore highly...
5.
Zhao W, Chen Y, Xiao J, Tang Z, Wang L, Ren Y, et al.
Am J Cancer Res
. 2024 Dec;
14(11):5351-5364.
PMID: 39659943
Primary analysis of the open-label, single-arm, phase II RENMIN-215 trial (primary data cutoff date: July 10, 2023) showed promising efficacy and tolerable safety with tislelizumab plus fruquintinib and fecal microbiota...
6.
Zhao W, Chen Y
Am J Cancer Res
. 2024 Dec;
14(11):5378-5388.
PMID: 39659937
Immune checkpoint inhibitor (ICI) has changed the situation of anti-tumor therapy. Several phase I/II clinical trials explored ICI-based combinations in microsatellite stable (MSS) metastatic colorectal cancer (mCRC) with mixed outcomes....
7.
Li J, Pan X, Guo L, Chen Y
Med Eng Phys
. 2024 Oct;
132:104207.
PMID: 39428130
Advances in cancer diagnostics play a pivotal role in increasing early detection of cancer. Integrating laser-induced breakdown spectroscopy (LIBS) with machine learning algorithms has attracted wide interest in cancer diagnosis....
8.
Chen Q, Pang M, Chen P, Zhou Z, Lei J, He B, et al.
Clin Transl Med
. 2024 Jul;
14(7):e1758.
PMID: 39073026
: CRISPR/Cas12a-based combinational screening has shown remarkable potential for identifying genetic interactions. Here, we describe an innovative method for combinational genetic screening with rapid construction of a dual-CRISPR RNA (crRNA)...
9.
Zhou Z, Lei J, Fang J, Chen P, Zhou J, Wang H, et al.
Int Immunopharmacol
. 2024 Jul;
139:112637.
PMID: 39033659
Cancer immunotherapies are ineffective in nonresponding patients due to absence of immune responses. Here, we identified that dihydroartemisinin (DHA) induced immunogenic cell death (ICD) in hepatocellular carcinoma (HCC), proved by...
10.
Xia L, Shi W, Cai Y, Liao Z, Huang Z, Qiu H, et al.
Int J Surg
. 2024 Jun;
111(1):70-79.
PMID: 38920327
Background: For stage T1b-2N0-1 esophageal cancer, the impact of neoadjuvant therapy plus surgery (NS), surgery alone (SA), and surgery plus adjuvant therapy (ST) on cancer-specific survival (CSS) and overall survival...